New daily persistent headache with a thunderclap headache onset and complete response to Nimodipine (A new distinct subtype of NDPH) by unknown
Rozen and Beams The Journal of Headache and Pain 2013, 14:100
http://www.thejournalofheadacheandpain.com/content/14/1/100CASE REPORT Open AccessNew daily persistent headache with a thunderclap
headache onset and complete response to
Nimodipine (A new distinct subtype of NDPH)
Todd D Rozen* and Jennifer L BeamsAbstract
At present new daily persistent headache is just a group of conditions that are connected based on the temporal
profile of their mode of onset. If new daily persistent headache is a true distinct syndrome like migraine then we
need to start to define subtypes that have specific effective treatments such has been noted for migraine sub-forms.
We present what we believe is the first recognized subtype of new daily persistent headache that which starts with a
thunderclap headache onset. A patient presented with a 13 month history of a daily headache from onset which
initiated as a thunderclap headache along with persistent acalculia. All neuroimaging studies for secondary causes
were negative. Nimodipine rapidly and completely alleviated her headache and associated neurologic symptoms.
We propose that this subtype of new daily persistent headache is caused by a very rapid increase in CSF tumor
necrosis factor alpha levels leading to cerebral artery vasospasm with a subsequent thunderclap headache, then
continuous or near continuous cerebral artery vasospasm leading to a persistent daily headache. Nimodipine
which not only inhibits cerebral artery vasospasm but also tumor necrosis factor alpha production appears to be
a specific treatment for this distinct subtype of new daily persistent headache.
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The lack of consensus on a clear definition of new daily
persistent headache (NDPH) and the fact that we are
still searching for adequate therapy reflects on how little
we know about this syndrome [1]. Is NDPH a group of
conditions that just happen to all start daily from onset
and have little else in common including no shared
underlying pathogenesis or is there some distinct cortical
change that causes a daily headache from onset in all
patients with NDPH although the mechanism by which
this cortical phenomena is triggered may be different
for individual patients (post-infectious, post-surgical
for example)? If NDPH is a distinct all-encompassing
syndrome like migraine then we need to define sub-forms
that may have specific effective treatments such has
been noted for migraine with aura for example [2]. The
end result of this will be improved patient satisfaction.* Correspondence: tdrozmigraine@yahoo.com
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reproduction in any medium, provided the origThe presented case appears to be the first documented
distinct subtype of NDPH: NDPH with a thunderclap
headache onset. The treatment for this distinct case of
NDPH is nimodipine.Case presentation
A 46-year-old woman presented with a daily headache
from onset that began 13 months prior. The daily headache
started as a thunderclap headache. She was playing bingo
and she suddenly developed the worst headache of her
life which peaked immediately to 10/10 in intensity
without latency. This was associated with vomiting and
dizziness. The peak headache lasted for approximately
24 hours and thereafter she was left with a persistent
lower grade headache which never waned. She denied
having any further thunderclap headaches. With the
original thunderclap headache she did not seek emergency
attention. She saw her PCP the following day and had
a brain MRI with and without gadolinium within 7
days which was reportedly normal with no evidenceis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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completed. Her persistent daily headache was typically
of moderate severity (4-5/10 VAS) and was localized
to the right occipito-nuchal region. There was never
any pain free time and she experienced intermittent
associated symptoms including nausea and photophobia.
She never experienced any cranial autonomic associated
symptoms. The patient denied any headache triggering or
alleviating maneuvers. She could not identify any precipi-
tating event just prior to the onset of her daily persistent
headache including no viral infection, stressful life event
and she had not had any surgical procedures. She was on
citalopram at the time of headache onset although she
denied the use of marijuana, ecstasy or pseudoephedrine.
In addition to head pain the patient also complained of
having issues with numbers including doing simple
addition and subtraction, recognizing the order of
numbers and even recognizing certain numbers. She
had to change her pin number multiple times because
she could not place the numbers in the correct order on a
keypad. She was even unable to copy down telephone
numbers. She worked as a pharmacist and was actually
very proficient in mathematics so the issue with numbers
and calculations was very troubling to her and she was at
risk of losing her job. Her acalculia (part spatial, part anar-
ithmetria) started the same day as her daily headache. Her
neurologic examination on presentation to the headache
clinic was intact including a normal neurovascular exam-
ination, normal language examination, normal ability to
read and write, but on serial 7 s testing she could not get
below 93 when starting at 100. She also could not copy
numbers in a correct order when they were presented to
her verbally. In addition she had right greater occipital
notch and occiput based pain to palpation although she
stated this palpable tenderness was not her true pain
which was “deep” to the skull. As the patient already had
brain neuroimaging, cerebral vessel imaging was ordered
to complete the evaluation for thunderclap headache and
this included CT angiography of the head and neck vessels
as well as brain venography and all studies were negative
including no evidence for aneurysms, vessel dissection,
vasospasm or thrombosis. An EEG was also completed
and this was a normal study. Prior failed therapies which
were minimal before coming to the dedicated headache
clinic included near daily over the counter analgesics
which were minimally effective, topiramate which lowered
daily headache intensity but did not provide any pain
free time and did not alter calculation issues, and oral
prednisone which reduced but did not eliminate her
headache (of note sedimentation rate and c-reactive
protein were normal). The patient was given a diagnosis of
NDPH as she met ICHD-3 beta criteria [3] which began
as a thunderclap headache. Her headache did not meet
criteria for hemicrania continua although it was one-sided.She also had persistent acalculia. As nothing was noted on
imaging the authors surmised that this may be a syndrome
of persistent vasospasm and possibly even reversible
cerebral vasoconstriction syndrome (RCVS) induced by
citalopram and the acalculia was caused by persistent
oligemia to the cortex. Citalopram was discontinued.
Nimodipine was started for preventive therapy at a dose of
30 mg PO BID and within 4 days of starting therapy
the patient became headache free. After 3 weeks on
nimodipine her acalculia resolved. On re-evaluation two
months after her initial visit she remained pain free. After
4 months on medication the patient decided to taper off
her nimodipine and her daily headaches returned almost
immediately although the calculation issues remained
resolved. Nimodipine was restarted at 30 mg bid and
within 3 days her headaches again ceased. This verified
that the nimodipine had cured her headaches and it
was not just being off citalopram. Over time she has
been able to reduce the dose to 30 mg one time per day
and still she remains headache free. She is hesitant to
come off the medication in fear the pain will return.
She has been followed for almost one year.
Conclusions
The question arises does this patient have a distinct
subtype of NDPH and if so was it caused by continuous
vasospasm and did the vasospasm lead to oligemia to
specific regions of the cortex which led to acalculia?
Based on the patient’s response to nimodipine (a known
inhibitor of cerebral artery vasoconstriction) this is a
distinct possibility. Isolated acalculia without agraphia
or alexia has been attributed to lesions mainly involving
the dominant parieto-temporal cortex but has also been
associated with injury to the medial frontal cortex, caudate
nucleus, internal capsule, putamen and can also involve
the non-dominant hemisphere when there is impairment
with spatial organization of numbers which this patient
displayed [4]. No ischemia was noted on this patient’s
brain MRI but that does not mean that one or more of
these cortical regions was not altered from persistent
oligemia; it just means that changes could not be seen by
conventional neuroimaging. We wanted to do SPECT or
PET imaging to better asses for changes in cortical
blood flow, but her medical insurance denied coverage
for this testing.
If vasospasm is the probable cause of NDPH with a
thunderclap headache onset then one needs to then
question if this subtype of NDPH is a prolonged subform
of RCVS and thus an overlap disorder that could be placed
under two ICHD sub-headings? In most instances RCVS
is a self-limited syndrome of individual thunderclap
headaches that by ICHD-3 beta criteria [3] does not
last longer than one month in duration [4]. However,
Hastriter et al. [5] in a Mayo Clinic series identified 16
Rozen and Beams The Journal of Headache and Pain 2013, 14:100 Page 3 of 4
http://www.thejournalofheadacheandpain.com/content/14/1/100patients with RCVS of whom six patients developed
chronic daily headache when followed over and average
of 99 weeks. The number of these patients who had a
presentation of daily persistent headache after their initial
thunderclap headache was not stated in the published
abstract, although five patients were documented to have
a continuous headache in between their thunderclap
headaches, thus a possible NDPH type picture. Treatment
for these patients was also not reported. In the Hastriter
et al. [5] population there was documented resolution
of vasoconstriction around 20 weeks after symptom onset,
thus the cause of the patient’s chronic headaches was
not felt to be from vasospasm and thus not known. It is
possible our patient was an outlier case of prolonged
RCVS and the result of persistent cerebral artery vasospasm
that lasted for more than one year’s duration, which was
not picked up on CT angiography, did not cause ischemia
on MRI, but did cause enough oligemia leading to acalculia
and head pain and nimodipine alleviated the vasospasm
and thus headache and neurologic symptoms; but this
can only be hypothesized. Conventional angiography
would have been helpful as it could have better identified
vasospasm but it was not completed as the patient so
quickly responded to treatment and we did not want to
subject her to another test which conceivably had a
stroke risk as a potential complication. What possibly
goes against the hypothesis of very prolonged vasospasm
for our patient is the data of Hastriter et al. [5] which
showed self-limited vasoconstriction even in those RCVS
patients who developed chronic daily headache. What also
is atypical for a diagnosis of RCVS is the fact that our
patient only experienced a single thunderclap headache
while most patients with RCVS have recurrent quick
peaking headaches. If indeed our patient had a daily
persistent headache secondary to RCVS or a sequela of
some other underlying phenomenon but the testing for
secondary causes is all negative then classification of this
disorder as a primary headache syndrome demonstrates
some of the limitations of the current ICHD criteria [3].
This patient’s headache did indeed meet the ICHD-3 beta
criteria [3] for primary NDPH as no secondary cause was
found on neuroimaging but with response to nimodipine
there is high clinical suspect the headache was at least
partially secondary to cerebral artery vasospasm. The
duration of time from onset of symptoms to when the
patient was seen at a dedicated headache clinic also
complicates issues with classification, as secondary causes
which may have been noted on imaging or other testing if
ordered properly at the onset of symptoms, may not be
present when ordered many months later, thus a correct
secondary diagnosis cannot be made at the time when a
patient is evaluated by a headache specialist. For NDPH
in particular where the underlying pathogenesis has
not been elucidated and in which most patients havenegative studies, classifying any form as primary NDPH
is actually difficult if not impossible, when all cases may
have a secondary underlying cause like the proposed
cerebral artery vasospastic issue in our case patient.
Nimodipine has shown very little effect in preventive
migraine studies [6]. Nimodipine has however shown
efficacy in the treatment of non-migrainous vascular
headaches in individuals with chronic brain ischemia
especially those with more significant headache intensity
[7]. The proposed mechanism of action for headache
control was inhibition of cerebral vasoconstriction. Nimo-
dipine has not previously been documented to have been
tried in NDPH [1]. There is recent animal data indicating
that nimodipine can decrease the expression of CGRP
in the trigeminal nucleus caudalis of rats [8]. As CGRP
is a known trigger of migraine attacks it conceivably may
also have a role in the pathogenesis of NDPH, another
trigeminal based pain syndrome [9]. Why nimodipine
however would be more effective for NDPH than for
migraine would be hard to understand if its effect was
solely by modulating CGRP expression. Nimodipine has
also been shown to inhibit glial activation and tumor
necrosis factor (TNF) alpha production in several animal
models and this could be one mechanism by which it may
work in NDPH [10,11]. One of the authors (TDR) has pre-
viously shown that patients with NDPH had elevation of
CSF TNF alpha levels and thus TNF alpha was a probable
inciting cytokine in the pathogenesis of this syndrome,
most likely thru its ability to produce CNS inflammation
[12]. TNF alpha also is a vasoconstrictive cytokine and
thus could have a distinct triggering potential in NDPH
with a thunderclap headache onset [13]. In mice TNF
alpha is able to evoke a direct vasoconstrictor effect on
isolated cerebral vessels through Rac-1 activation [13].
In humans there is anecdotal evidence that TNF alpha
plays a role in cerebral artery vasospasm as demonstrated
by peak elevations of CSF TNF alpha levels on the days
corresponding to peak vasospasm time in patients who
have had a subarachnoid hemorrhage and in those showing
elevated flow velocities on transcranial doppler after a
subarachnoid bleed [14]. We can thus hypothesize that
the syndrome of NDPH with a thunderclap headache
onset is caused by a very rapid increase in CSF TNF
alpha levels leading to cerebral artery vasospasm with a
subsequent thunderclap headache, then continuous or
near continuous cerebral artery vasospasm leading to a
persistent daily headache and possibly other neurologic
sequelae. To prove this hypothesis a csf analysis would need
to be completed at the time of NDPH and thunderclap
headache onset and it would need to demonstrate TNF
alpha levels higher than that noted in the author’s prior csf
study in typical NDPH without a thunderclap headache
onset. This could not be done in this patient as we
met her 13 months after symptom onset. Nimodipine
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in a dual fashion by directly inhibiting cerebral artery
vasospasm (calcium channel effect) and also by inhibiting
TNF alpha production which not only prevents cerebral
artery vasospasm, but in addition blocks the TNF alpha
cytokine inflammatory response a proposed trigger of
NDPH pain.
As NDPH is recognized as one of the most treatment
refractory of all chronic headache conditions, documenting
treatment responsive subtypes will be beneficial to both
patients and providers. How rare is the subtype of NDPH
with a thunderclap headache onset is unknown at present.
The authors can state that in their practice which has
a certain bias for NDPH patients, that this is the only
patient who has fit this exact clinical presentation over the
past year. Two other patients had a similar presentation of
daily headache after a thunderclap headache onset with
complete relief of their syndrome with nimodipine, but
both had multiple thunderclap headaches during the
first month of onset of their NDPH and thus were felt
to be more consistent with a variant of RCVS and in line
with the Hastriter et al. [5] reported patients, while our
above reported case subject had only a single thunderclap
headache at the outset of her daily persistent headache
with no other recurrent thunderclaps, which distinguished
her clinical presentation and placed it more in line in our
opinion with an NDPH variant. It is certainly important
when taking an NDPH history to ascertain what was
the presentation of the original headache because if it
was thunderclap then the provider should not only do
the proper secondary work-up (neuroimaging should
include MR angiography of the head and neck vessels,
MR venography, MRI brain with and without gadolinium
and a lumbar puncture if the patient is seen in the acute
headache setting) but they should now think of nimodipine
as a possible treatment option, which at present has not
been part of the typical NDPH treatment protocol. There
are two other case reports in the literature that should be
mentioned which have some similarities to the present
case report. A case of juvenile myoclonic epilepsy published
by one of the authors (TDR) in which treatment of an
associated neurologic condition in this case epilepsy
with lamotrigine led to alleviation of NDPH which mimics
our present case in which treatment of probable under-
lying vasospasm and TNF alpha elevation with nimodipine
alleviated co-associated NDPH [15]. A second case report
where NDPH was preceded by an acute clinical event
also known to be associated with an elevation of TNF
alpha, in this case heat stroke, and with no other
secondary medical issues noted [16]. In conclusion the
hope is that this present case will stimulate others to
publish cases of NDPH with a thunderclap headache onset
to determine how rare or common this presentation of
NDPH truly is.Consent
Patient gave signed consent for case report.
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